Results 231 to 240 of about 465,548 (350)

Delayed Diagnosis of Sézary Syndrome: Lessons From a Psoriasiform Presentation. [PDF]

Clin Case Rep
Neupane S, Neupane A, Khan SA, Kausar H.
europepmc   +1 more source

Clinical features and incidence of central nervous system involvement in patients with adult T‐cell leukaemia/lymphoma

British Journal of Haematology, EarlyView.
Summary Central nervous system (CNS) involvement is a known complication of adult T‐cell leukaemia/lymphoma (ATL), but its clinical characteristics and incidence still remain unclear. This study characterized the clinical features and incidence of CNS involvement in patients with ATL (CNS‐ATL).
Takuya Ueno, Makoto Yoshimitsu, Momone Sameshima, Taichi Nagano, Rika Akahoshi, Yusetsu Takeshita, Aya Shodai, Kodai Shima, Naosuke Arima, Yuhei Kamada, Daisuke Nakamura, Kenji Ishitsuka   +11 more
wiley   +1 more source

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy

British Journal of Pharmacology, EarlyView.
Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma. [PDF]

Front Immunol
Huang L, Guo H, Teng Y, Pang D, Zhang F, Sun Y, Ong CK, Tan J, Li W.   +8 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Acute renal failure as the initial presentation of T-lymphoblastic lymphoma: A case report. [PDF]

Clin Nephrol Case Stud
Darwish N, Lightle A.
europepmc   +1 more source

Multistep tumorigenesis in peripheral T cell lymphoma

International journal of hematology, 2015
M. Sakata-Yanagimoto
semanticscholar   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source